v3.25.1
Accounts Payable and Accrued Expenses
12 Months Ended
Dec. 31, 2024
Accounts Payable and Accrued Expenses [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses as of December 31, 2024 and 2023 consisted of:

 

   December 31,
2024
   December 31,
2023
 
         
Deferred bonus and salaries payable  $
-
   $451,660 
Research and development expenses payable   778,205    1,162,155 
Professional fees payable   127,031    175,324 
Cost of healthcare services payable   
-
    61,826 
Insurance expenses payable   
-
    27,463 
Others   13,375    15,913 
   $918,611   $1,894,341 

 

On March 31, 2023, the Group entered into exchange agreements and cancelled 177,667 existing vested and unvested share options held by related parties option holders and cancelled its obligations for deferred cash bonus payables of $3.1 million by granting 403,820 share options with 6 months vesting period (see Note 17). The settlement of obligations of $3.1 million deferred cash bonus payables was deemed as capital contribution from related parties and was credited to additional paid-in capital.

 

On March 31, 2023, the Group entered into exchange agreements and cancelled 70,428 existing vested and unvested share options held by non-related parties option holders and cancelled its obligations for deferred cash bonus payables of $1.6 million by issuance of 70,430 fully vested Class A Ordinary Shares (see Note 16). The reversal of deferred cash bonus payables for $1.0 million and $0.6 million was credited to research and development expenses and general and administrative fees, respectively.